Effects of lithium on oxidative stress and behavioral alterations induced by lisdexamfetamine dimesylate: Relevance as an animal model of mania

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 43, Issue , 2013, Pages 230-237

  Macêdo, Danielle S ^a   de Lucena, David F ^b   Queiroz, Ana Isabelle G ^a   Cordeiro, Rafaela C ^a   Araújo, Maíra M ^a   Sousa, Francisca Cléa ^a   Vasconcelos, Silvânia M ^a   Hyphantis, Thomas N ^c   Quevedo, João ^d   McIntyre, Roger S ^e,f   Carvalho, André F ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b Faculty of Medicine Christus   (Brazil)

^c UNIVERSITY OF IOANNINA   (Greece)

^d UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

D amphetamine; Lisdexamfetamine dimesylate; Lithium; Mania model; Oxidative stress

Indexed keywords

GLUTATHIONE; LISDEXAMFETAMINE; LITHIUM SALT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; HIPPOCAMPUS; LIPID PEROXIDATION; LOCOMOTION; MALE; MANIA; NONHUMAN; OXIDATIVE STRESS; PREFRONTAL CORTEX; RAT; TREATMENT RESPONSE;

ANIMALS; ANTIMANIC AGENTS; BEHAVIOR, ANIMAL; BIPOLAR DISORDER; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; HIPPOCAMPUS; LIPID PEROXIDATION; LITHIUM; LITHIUM CARBONATE; MALE; MOTOR ACTIVITY; NEOSTRIATUM; OXIDATIVE STRESS; PREFRONTAL CORTEX; RATS; RATS, WISTAR; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 84873284223     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.01.007     Document Type: Article

References (50)

1. Andreazza A.C., Cassini C., Rosa A.R., Leite M.C., de Almeida L.M., Nardin P., et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007, 41:523-529.
2. Andreazza A.C., Kauer-Sant'Anna M., Frey B.N., Stertz L., Zanotto C., Ribeiro L., et al. Effects of mood stabilizers on DNA damage in an animal model of mania. J Psychiatry Neurosci 2008, 33:516-524.
3. Andreazza A.C., Kapczinski F., Kauer-Sant'Anna M., Walz J.C., Bond D.J., Goncalves C.A., et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci 2009, 34:263-271.
4. Archer J. Tests for emotionality in rats and mice: a review. Anim Behav 1973, 21:205-235.
5. Beauchaine T.P., Neuhaus E., Zalewski M., Crowell S.E., Potapova N. The effects of allostatic load on neural systems subserving motivation, mood regulation, and social affiliation. Dev Psychopathol 2011, 23:975-999.
6. Beaulieu J.M., Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011, 63:182-217.
7. Behrens M.M., Sejnowski T.J. Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?. Neuropharmacology 2009, 57:193-200.
8. Berk M. Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int J Neuropsychopharmacol 2009, 12:441-445.
9. Berk M., Dodd S., Kauer-Sant'anna M., Malhi G.S., Bourin M., Kapczinski F., et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl 2007, 434:41-49.
10. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011, 35:804-817.
11. Berman S.B., Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 1999, 73:1127-1137.
12. Breuillaud L., Rossetti C., Meylan E.M., Merinat C., Halfon O., Magistretti P.J., et al. Deletion of CREB-regulated transcription coactivator 1 induces pathological aggression, depression-related behaviors, and neuroplasticity genes dysregulation in mice. Biol Psychiatry 2012, 14:14.
13. da-Rosa D.D., Valvassori S.S., Steckert A.V., Ornell F., Ferreira C.L., Lopes-Borges J., et al. Effects of lithium and valproate on oxidative stress and behavioral changes induced by administration of m-AMPH. Psychiatry Res 2012, 17:17.
14. das Neves Duarte J.M., Kulak A., Gholam-Razaee M.M., Cuenod M., Gruetter R., Do K.Q. N-acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development. Biol Psychiatry 2012, 71:1006-1014.
15. Dennehy E.B., Marangell L.B., Allen M.H., Chessick C., Wisniewski S.R., Thase M.E. Suicide and suicide attempts in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Affect Disord 2011, 133:423-427.
16. Dent M.F., Neill D.B. Dose-dependent effects of prefrontal dopamine on behavioral state in rats. Behav Neurosci 2012, 27:27.
17. Draper H.H., Squires E.J., Mahmoodi H., Wu J., Agarwal S., Hadley M. A comparative evaluation of thiobarbituric acid methods for the determination of malondialdehyde in biological materials. Free Radic Biol Med 1993, 15:353-363.
18. Drevets W.C., Gautier C., Price J.C., Kupfer D.J., Kinahan P.E., Grace A.A., et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001, 49:81-96.
19. Einat H. Modelling facets of mania - new directions related to the notion of endophenotypes. J Psychopharmacol 2006, 20:714-722.
20. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82:70-77.
21. Fiorino D.F., Phillips A.G. Facilitation of sexual behavior and enhanced dopamine efflux in the nucleus accumbens of male rats after d-amphetamine-induced behavioral sensitization. J Neurosci 1999, 19:456-463.
22. Flaisher-Grinberg S., Kronfeld-Schor N., Einat H. Models of mania: from facets to domains and from animal models to model animals. J Psychopharmacol 2010, 24(3):437-438. [Mar, Epub 2008 Oct 6.; 2010].
23. Fleckenstein A.E., Volz T.J., Riddle E.L., Gibb J.W., Hanson G.R. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 2007, 47:681-698.
24. Frey B.N., Andreazza A.C., Ceresér K.M.M., Martins M.R., Valvassori S.S., Réus G.Z., et al. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci 2006, 79:281-286.
25. Frey B.N., Valvassori S.S., Reus G.Z., Martins M.R., Petronilho F.C., Bardini K., et al. Changes in antioxidant defense enzymes after d-amphetamine exposure: implications as an animal model of mania. Neurochem Res 2006, 31:699-703.
26. Frey B.N., Valvassori S.S., Reus G.Z., Martins M.R., Petronilho F.C., Bardini K., et al. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 2006, 31:326-332.
27. Graham D.G., Tiffany S.M., Bell W.R., Gutknecht W.F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978, 14:644-653.
28. Harrison-Read P.E. Models of mania and antimanic drug actions: progressing the endophenotype approach. J Psychopharmacol 2009, 23(3):334-337. [May, Epub 2008 Jun 26.; 2009].
29. Hopkins H.S., Gelenberg A.J. Serum lithium levels and the outcome of maintenance therapy of bipolar disorder. Bipolar Disord 2000, 2:174-179.
30. Jasinski D.R., Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009, 23:419-427.
31. Kapczinski F., Vieta E., Andreazza A.C., Frey B.N., Gomes F.A., Tramontina J., et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008, 32:675-692.
32. Kleijn J., Wiskerke J., Cremers T.I., Schoffelmeer A.N., Westerink B.H., Pattij T. Effects of amphetamine on dopamine release in the rat nucleus accumbens shell region depend on cannabinoid CB1 receptor activation. Neurochem Int 2012, 60:791-798.
33. Ko J.H., Strafella A.P. Dopaminergic neurotransmission in the human brain: new lessons from perturbation and imaging. Neuroscientist 2012, 18:149-168.
34. Kolar D., Keller A., Golfinopoulos M., Cumyn L., Syer C., Hechtman L. Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat 2008, 4:107-121.
35. Lenaz G., D'Aurelio M., Merlo Pich M., Genova M.L., Ventura B., Bovina C., et al. Mitochondrial bioenergetics in aging. Biochim Biophys Acta 2000, 15:2-3.
36. Lipska B.K., Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 2000, 23:223-239.
37. Macedo D.S., Medeiros C.D., Cordeiro R.C., Sousa F.C., Santos J.V., Morais T.A., et al. Effects of alpha-lipoic acid in an animal model of mania induced by d-amphetamine. Bipolar Disord 2012, 14(7):707-718. [Nov].
38. Machado-Vieira R., Andreazza A.C., Viale C.I., Zanatto V., Cereser V., da Silva Vargas R., et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007, 421:33-36.
39. Mattingly G. Lisdexamfetamine dimesylate: a prodrug stimulant for the treatment of ADHD in children and adults. CNS Spectr 2010, 15:315-325.
40. McIntyre R.S., Rosenbluth M., Ramasubbu R., Bond D.J., Taylor V.H., Beaulieu S., et al. Managing medical and psychiatric comorbidity in individuals with major depressive disorder and bipolar disorder. Ann Clin Psychiatry 2012, 24:163-169.
41. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nat Neurosci 2010, 13:1161-1169.
42. NIH Guide for the care and use of laboratory animals - Institute of Laboratory Animal Research - National Research Council 1996, National Academies Press.
43. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat 2010, 6:317-327.
44. Post R.M. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev 2007, 31:858-873.
45. Riegel R.E., Valvassori S.S., Elias G., Reus G.Z., Steckert A.V., de Souza B., et al. Animal model of mania induced by ouabain: evidence of oxidative stress in submitochondrial particles of the rat brain. Neurochem Int 2009, 55:491-495.
46. Rowley H.L., Kulkarni R., Gosden J., Brammer R., Hackett D., Heal D.J. Lisdexamfetamine and immediate release d-amfetamine - differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activity. Neuropharmacology 2012, 63:1064-1074.
47. Scheffer R.E., Kowatch R.A., Carmody T., Rush A.J. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry 2005, 162:58-64.
48. Soreca I., Fagiolini A., Frank E., Houck P.R., Thompson W.K., Kupfer D.J. Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder. J Psychiatr Res 2008, 42:956-961.
49. Steullet P., Cabungcal J.H., Kulak A., Kraftsik R., Chen Y., Dalton T.P., et al. Redox dysregulation affects the ventral but not dorsal hippocampus: impairment of parvalbumin neurons, gamma oscillations, and related behaviors. J Neurosci 2010, 30:2547-2558.
50. Yang Y., Dieter M.Z., Chen Y., Shertzer H.G., Nebert D.W., Dalton T.P. Initial characterization of the glutamate-cysteine ligase modifier subunit Gclm(-/-) knockout mouse. Novel model system for a severely compromised oxidative stress response. J Biol Chem 2002, 277:49446-49452.